Vanguard Global Advisers
ARTV

Vanguard Global Advisers’s Artiva Biotherapeutics ARTV Stock Holding History

Vanguard Global Advisers’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Buy
+11,978
New +$109K ﹤0.01% 2715

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Vanguard Global Advisers's ARTV Position: Q2 2026 in Review

Vanguard Global Advisers opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 11,978 shares worth $116K. The stake represents ﹤0.01% of the portfolio and ranks #2715 among its holdings.

73 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Vanguard Global Advisers held 11,978 shares of Artiva Biotherapeutics worth $116K as of Q2 2026.
  • Artiva Biotherapeutics was a new Vanguard Global Advisers position in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2715 holding.
  • 73 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.